<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="124">
  <stage>Registered</stage>
  <submitdate>4/08/2005</submitdate>
  <approvaldate>4/08/2005</approvaldate>
  <actrnumber>ACTRN12605000073606</actrnumber>
  <trial_identification>
    <studytitle>A non-randomised trial evaluating in-field control following the addition of involved-field radiotherapy to transplantation for patients with Hodgkins Disease and non-Hodgkins Lymphoma: An ALLG/TROG Prospective Multicentre Study</studytitle>
    <scientifictitle>A non-randomised trial evaluating in-field control following the addition of involved-field radiotherapy to transplantation for patients with Hodgkin's Disease and non-Hodgkin's Lymphoma: An ALLG/TROG Prospective Multicentre Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Australasian Leukaemia and Lymphoma Group (ALLG): ALLG HDNHL4</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hodgkin's disease </healthcondition>
    <healthcondition>Non-Hodgkins lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A prospective non randomised trial evaluating the rate of in-field failure in patients having protocol radiotherapy with transplantation for Hodgkin's and non-Hodgkin's lymphoma.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine the cumulative incidence of progression in irradiated pre-transplant sites of failure</outcome>
      <timepoint>3 years following commencement of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Determine the cumulative incidence of progression outside pre-transplant sites of failure</outcome>
      <timepoint>3 years following commencement of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Determine overall progression free survival and time to progression</outcome>
      <timepoint>At 3 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Assess selected toxicities attributable to protocol RT</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine overall survival</outcome>
      <timepoint>At 3 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Document the time to haematological recovery from post-transplant RT-induced cytopaenia, which occurs after a progenitor cell infusion, and the duration of recovery.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. Assess the prognostic significance of conventional and functional imaging response to cytoreduction chemotherapy.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histological diagnosis of HD or NHL other than follicular grade I-II, small lymphocytic and marginal zone lymphoma; 2. Failure to achieve CR with first line therapy, or relapse after CR to first line therapy*; 3. No more than 2 lines (ie regimens) of cytoreduction chemotherapy; 4. At least a 50% reduction in the sum of products of tumour diameters following cytoreduction chemotherapy (NHL only); 5. Sites of failure confined to lymph nodes, spleen, Waldeyer's ring and limited extra-nodal sites (solitary soft tissue deposit or single bone or one kidney or extension from nodal site into contiguous lung, pleura, pericardium, neural structure or liver) that can be treated within a tolerable RT field (histological evidence of bone marrow relapse is also permissible); 6. Sites of failure are adequately documented for RT planning; 7. The patient is planned to undergo autologous transplantation; 8. Confirmation of adequate progenitor cell harvest (&gt; 2x106 CD34+ve cells/Kg); 9. The patient's age is at least 18; 10. The patient's ECOG performance status is two or less; 11. The patient has provided written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Prior dose-limiting RT to site requiring RT; 2. Planned TBI-based conditioning; 3. Sites of failure include haematogenous involvement of lung or liver parenchyma, brain or both kidneys; 4. Sites of failure include diffuse or disseminated involvement of pleura/pericardium, spinal cord/spinal meninges, bone or skin/soft tissue; 5. Any condition which in the opinion of the investigators puts patients at undue risk of RT toxicity; 6. Women who are pregnant or breast feeding 7. Patients who are not using adequate contraception (if relevant).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>9/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Royal Australian and New Zealand College of Radiologists</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Peter MacCallum Cancer Centre Division of Radiation Oncology</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Amgen Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Baxter Healthcare Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname> Christchurch</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Newcastle</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname> Peter MacCallum</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Andrew Wirth</name>
      <address>Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002</address>
      <phone>+61 3 96561111</phone>
      <fax>+61 3 96561424</fax>
      <email>email andrew.wirth@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Andrew Wirth</name>
      <address>Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002</address>
      <phone>+61 3 96561111</phone>
      <fax>+61 3 96561424</fax>
      <email>email andrew.wirth@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>